FLDM: Multi-Site Study of COVID-19 Patients Utilizing Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay

New alert via PocketInfo for FLDM:

Multi-Site Study of COVID-19 Patients Utilizing Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay

Press Releases: http://www.fluidigm.com/press-releases.html
SEC Filings: http://investors.fluidigm.com/sec.cfm
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8